In Focus, December 2008

Article

All the latest news and industry developments in focus, December 2008

Please click on any of the headlines below to see the full story.

DR study: 25 year results
Although there is a relatively high rate of diabetic retinopathy (DR) progressing to proliferative diabetic retinopathy (PDR), the level of PDR care available has improved, according to 25-year results of the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), published in the November issue of Ophthalmology

ARVO to award young scientists
A series of awards granted to scientists under the age of 45 has been announced by the Association for Research in Vision and Ophthalmology (ARVO) Foundation for Eye Research (AFER) and Merck & Co, Inc. 

Regrowth of optic nerve cells achieved
It may be possible to regenerate optic neural axons by manipulating growth control pathways, according to study results published in the 7 November issue of the journal Science

Anti-VEGFs may cause blindness
Long-term use of anti-vascular endothelial growth factor (VEGF) drugs should be treated with caution because endogenous VEGF plays an important role in the maintenance of retina neuronal cells, according to study results published by PLoS ONE on the 3rd November. 

Treating paediatric convergence
Office-based vergence/accommodative therapy with home reinforcement (OBVAT) is the most effective method of treating symptomatic convergence insufficiency when compared with any other home- or office-based placebo or therapy, according to study results published in the October issue of the Archives of Ophthalmology

Night vision and AMD
Problems with night vision correlate to an increase in the risk of symptoms of both the wet and dry forms of age-related macular degeneration (AMD), according to study results published in the November issue ofOphthalmology

Blindness risk double in men
Despite the higher rate of prevalence in women, it is men who are more likely to suffer severe vision loss as a result of idiopathic intracranial hypertension (IIH), according to study results published online ahead of print by Neurology

 

For up-to-date news and announcements, please check the latest news section of our website. Alternatively, please sign up for our weekly newsletter.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.